Publications (2)1.83 Total impact
-
Article: Immunoglobulin levels in panic disorder patients.
[show abstract] [hide abstract]
ABSTRACT: The study was conducted to evaluate the serum immunoglobulin levels in patients suffering from panic disorder and to assess the relationship between the changes of immunoglobulin levels and the socioeconomic parameters, as well as nutritional status. 54 panic patients were randomly selected from the Department of Psychiatry, Bangabandhu Sheikh Mujib Medical University (BSMMU) and Dhaka Medical College Hospital, Bangladesh. Fifty two, age and gender matched healthy volunteers (42 males and 10 females, mean age of 30 ± 6 yrs) were also enrolled in this study. Immunoglobulin levels were measured by turbidimetry method using immunoglobulin kits. It was found that the mean serum immunoglobulin concentrations of IgG, IgM and IgA of panic disorder patients were 0.999±0.26 (g/L), 0.1±0.028 (g/L) and 0.194±0.066 (g/L) respectively whereas the values were 1.24± 0.39 ( g/L ), 0.096±0.022 ( g/L) , 0.194±0.053 (g/L) in healthy volunteers. IgG level in panic disorder patient was found significantly (p <0.05) lower than that of the controls but the change in concentration of IgM and IgA were not significant (p=0.497, p=0.962). Socioeconomic data reveals that most of the patients were from lower income group and educated. BMI (Mean±SD) of the patients (22.62 ± 3.74 kg/m2) and controls (23.74 ± 2.71 kg/m2) were well within the normal range. From correlative analysis it has been found that income has significant effect (p=0 .047) on the change of the serum IgG level in panic disorder patient and it was also been justified by the regression analysis (p=0.049). This finding may play a key role in the diagnosis and treatment of the panic disorder patients. Further studies have been suggested with a large number of populations to confirm these findings.Pakistan journal of pharmaceutical sciences 01/2012; 25(1):149-53. · 1.10 Impact Factor -
Article: Relative bioavailability and pharmacokinetic study of two trimetazidine modified release formulations in healthy Bangladeshi male volunteers.
[show abstract] [hide abstract]
ABSTRACT: Trimetazidine (CAS 5011-34-7) is an effective and well-tolerated antianginal drug that possesses protective properties against ischemia-induced heart injury. The relative bioavailability and pharmacokinetic characteristics of two modified release formulations of 35 mg trimetazidine, one as the test product (Metacard MR) and one as the reference product, were compared in healthy Bangladeshi male volunteers. The randomized, two-way crossover study was conducted in 24 healthy male volunteers after administration of a single 35 mg dose of each modified release formulation after 12-h overnight fasting, with a washout period of two weeks. Blood samples were collected at various time intervals following oral administration and analyzed for trimetazidine concentrations using a validated HPLC method. The pharmacokinetic parameters were determined by a non-compartmental method. After administering a single dose of 35 mg of each trimetazidine formulation, the obtained mean (SD) values for the test and reference products were 104.78 (29.3) and 98.57 (28.7) ng/ml for Cmax; 4.00 (1.1) and 3.54 (1.32) h for t(max); 423.81 (173.9) and 410.01 (195.87) ng x h/ml for AUC0-12; and 472.51 (195.2) and 462.78 (225.13) ng x h/ml for AUC0-infinity respectively. The mean t1/2 was found 3.69 (1.1) h and 3.45 (0.72) h for test and reference products respectively. From paired t-test, no significant differences were observed (p > 0.05) for any pharmacokinetic parameters. The 90% confidence intervals of the test/reference mean ratios of the In-transformed AUC0-12, AUC0-infinity, and Cmax mean values were 106.19% (97.16%-116.06%), 104.74% (95.04%-115.42%) and 106.30% (95.23%-118.66%), respectively. The two formulations demonstrated similar bioavailability with respect to both the rate and extent of trimetazidine absorption.Arzneimittel-Forschung 01/2011; 61(7):393-8. · 0.72 Impact Factor
